molecular prognostication in essential thrombocythemia and polycythemia vera: does it matter?
Published 9 years ago • 1.4K plays • Length 17:25Download video MP4
Download video MP3
Similar videos
-
22:40
treatment goals in essential thrombocythemia and polycythemia vera
-
13:49
“masked” polycythemia vera and polycythemia vera “in evolution”
-
17:02
indication for cytoreductive therapy in et and pv: do we have it right?
-
20:15
hydroxyurea intolerance/resistance in polycythemia vera
-
17:54
current therapy options and clinical outcomes analysis in patients with pv
-
22:18
use of molecular genetic testing in mds and mpn
-
7:58
essential thrombocytosis (et) | myeloproliferative neoplasm (jak2 kinase)
-
1:10
differences between polycythemia vera and essential thrombocythemia
-
23:17
mutations in myelofibrosis: which to test for, when and why
-
21:27
topical challenges in the management of et
-
27:23
interactive case: jak inhibitors for the successful management of polycythemia vera
-
4:22
molecular profile impacts platelet function and thrombin generation in essential thrombocythemia
-
21:43
hydroxyurea intolerance/resistance in polycythemia vera
-
23:34
is there a role for jak inhibitors in essential thrombocythemia (et)?
-
23:14
why is hydroxyurea first line therapy in the us for essential thrombocythemia?
-
3:06
the unmet needs of essential thrombocythemia and polycythemia vera patients
-
3:25
understanding the molecular pathophysiology of polycythemia vera
-
12:42
essential thrombocythemia etiology. calr (calreticulin) mpl jak2 mutation. molecular pathogenesis
-
23:39
expert perspectives: jak inhibitors for polycythemia vera